

JOHN K RAMAGE
CURRICULUM VITAE

2019

PERSONAL DETAILS:

Name: John K Ramage

Date of birth: GRO/55

Address: GRO-C

Place of Birth: GRO-C Kent.

Nationality: British

Qualifications: MB BS University of London 1978

MRCP(UK) 1984

MD University of London 1989.

FRCP (London) May 1999

PRESENT POST:

Consultant physician in Gastroenterology and Hepatology,
North Hampshire Hospital, Aldermaston Rd Basingstoke,
Hants, RG24 9NA.

Honorary Consultant and lead clinician for Neuroendocrine
Services, Institute of liver studies, Kings College Hospital.

Hon Senior Lecturer. Kings College London.

Visiting Professor University of Winchester

PREVIOUS APPOINTMENTS since consultant :

May 1994-May96	Consultant physician and gastroenterologist, Conquest hospital, Hastings.
May 96-present	Consultant physician and gastroenterologist, North Hampshire Hospital, Basingstoke.
May 1994- present	Hon consultant, Institute of liver studies, Kings College Hospital, London.

MEMBERSHIP OF SOCIETIES:

Member, British Society of Gastroenterology.

Member, British Association for Study of the Liver.

GMC Full registration. Number: 2425553

Medical Protection Society. Number 150416.

Over 100 peer reviewed papers published to date.

LIST OF PUBLICATIONS.

1. **Ramage JK**. Bullet and missile wounds in Northern Ireland. J Royal Naval Med Serv. 1982;68:82-86.
2. Ireland A, Colin-Jones DG, Gear P, Golding PL, **Ramage JK**, et al. Ranitidine 150mg twice daily vs 300mg nightly in the treatment of duodenal ulcers. Lancet 1984;2:274-276.
3. Colin-Jones DG, Ireland A, Gear P, Golding PL, **Ramage JK** et al. Reducing overnight secretion of acid to heal duodenal ulcers. Comparison of standard divided dose of ranitidine with a single dose administered at night. Am J Med 1984;77:116-22.
4. Deakin M, **Ramage JK**, Gray SP, Billings J, Colin-Jones D, Williams JG. Smoking, gastric secretion and inhibition by H₂ receptor antagonists. Lancet 1985;1:1049.
5. Deakin M, **Ramage J**, Paul A, Gray SP, Billings J, Williams JG. Don't freeze pepsin! J Royal Naval Med Serv. 1982;68:82-86.
6. **Ramage JK**, Denton A, Williams JG. Inhibition of food-stimulated acid secretion by misoprostol, an orally-active synthetic E₁ analogue prostaglandin. British Journal of Clinical Pharmacology 1985;19:9-12.
7. Deakin M, **Ramage JK**, Paul A, Gray SP, Billings J, Williams JG. Effect of enprostil, a synthetic prostaglandin E₂ on 24 hour intragastric acidity, nocturnal acid and pepsin secretion. Gut 1986;27:1054-1057.
8. Williams JG, Deakin M, **Ramage JK**. Effect of cimetidine and pirenzepine in combination on 24-hour intragastric acidity in patients with duodenal ulceration. Gut 1986;27:428-32.
9. Deakin M, Glenny HP, **Ramage JK**, Mills JG, Burland WL, Williams JG. Large single daily dose of histamine H₂ receptor antagonist for duodenal ulcer. How much and when? A clinical pharmacology study. Gut 1987;28:566-572.
10. **Ramage JK**, Hunt RH, Perdue MH. Changes in intestinal permeability and epithelial differentiation during inflammation in the rat. Gut 1988;29:57-61.

11. Jenkins RT, **Ramage JK**, Jones DB, Collins SM, Goodacre RL, Hunt RH. Small bowel and colonic permeability to ⁵¹Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med 1988;11:151-155.
12. **Ramage JK**, Stanis A, Scicchitano R, Hunt RH, Perdue MH. Effect of immunological reactions on rat intestinal epithelium. Correlation of increased intestinal permeability to ⁵¹Cr-EDTA and ovalbumin during acute inflammation and anaphylaxis. Gastroenterology 1988;94:1368-1375.
13. Perdue MH, **Ramage JK**, Burget D, Marshall J, Masson S. Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during Nippostrongylus-induced inflammation in the rat. Digestive Diseases and Sciences 1989;34:724-731.
14. **Ramage JK**, Hunt RH. Vindaloo and you. British Medical Journal 1989;298:30. (letter).
15. **Ramage JK**, Miller ARO, Clarke PD. Acute diarrhoea in expatriates in Bangladesh. Gut 1990;31:123 (Letter)
16. D'Inca R, **Ramage JK**, Hunt RH, Perdue MH. Antigen-induced mucosal damage and restitution in the small intestine of the immunised rat. Int Arch Allergy Appl Immunol 1990;91:270-277.
17. **Ramage JK**, Kirkham N, Doyle T, Cairns SR. Gangliocytic paraganglioma causing obstructive jaundice treated by endoscopic stenting in a patient with neurofibromatosis and nodular regenerative hyperplasia of the liver. European Journal of Gastroenterology and Hepatology 1991;3:851-854.
18. **Ramage JK**. Ectopic Variceal Bleeding. Gastrointestinal Endoscopy Clinics of North America 1992;2:95-109.
19. Gimson AES, **Ramage JK**, Panos M, Hayllar K, Harrison P, Westaby D, Williams R. Randomised controlled trial of variceal banding ligation and injection sclerotherapy for bleeding oesophageal varices. Lancet 1993;342:391-94.
20. Gane E, Portmann B, Saxena R, Wong P, **Ramage JK**, Williams R. Nodular regenerative hyperplasia of the liver following liver transplantation. Hepatology 1994 ;20:88-94.

21. **Ramage JK**, Hale A, Gane E et al. Persistent parvovirus B-19 infection in a liver transplant recipient; treatment with plasmapheresis. *Lancet* 1994;343:667-668. (letter).
22. Rizzi PM, Kane PA, Ryder SD, **Ramage JK**, Gane E, Tan KC, Portmann B, Karani J, Williams R. Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation. *Gastroenterology* 1994;107:1425-1429.
23. Wong P, Devlin J, Gane E, **Ramage J**, Portmann B, Williams R FK 506 rescue therapy for intractable liver allograft rejection *Transpl Int.* 1994;7 Suppl 1:S70-6.
24. Uddin W, **Ramage JK**, Portmann B, Wilson P, Benjamin I, Tan K-C, Williams R. Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. *Gut* 1995;1:142-145.
25. Rizzi P, **Ramage JK**, Portmann B, Williams R. Neoadjuvant chemotherapy after liver transplantation for hepatocellular carcinoma . *Transplantation proceedings* 1994; 26 : 4168-9.
26. Wong PYN, Devlin J, Gane E, **Ramage J**, Williams R. FK506 rescue therapy for intractable liver allograft rejection. *Transplant International* 1994;7:70-76.
27. McKay DM, **Ramage J**, Rangachari PK, Perdue MH. Effect of region, temperature and neuronal blockade on sodium and ⁵¹Cr-EDTA transport across canine gastrointestinal mucosa in-vitro. *Comparative biochemistry and physiology* 1994;107:711-7.
28. **Ramage JK**, Donaghy A, Farrant JM, Iorns R, Williams R. The use of serum tumour markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. *Gastroenterology* 1995; 108: 865-9.
29. Routley D, **Ramage JK**, McPeake J, Tan KC, Williams R. Orthotopic Liver Transplantation in the treatment of metastatic neuroendocrine tumors. *Liver transplantation and surgery* 1995;1:118-121.
30. Rizzi P, Ryder S , Portmann B, **Ramage JK**, Naoumov N Williams R. p53 protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. *Gut.* 1996;38:265-268.

31. **Ramage JK**, Catnach S, Williams R. Overview: The management of metastatic carcinoid tumours . Liver transplantation and surgery 1995; 1:107-110.
32. Gane EJ, Tibbs CJ, **Ramage JK**, Portmann BC, Williams R. Ribavirin therapy for hepatitis C infection following liver transplantation. Transplant International 1995;8:61-64.
33. Fox K, **Ramage JK**. An often forgotten treatable cause of lymphocytic meningo-encephalitis. Hospital Update.1996.
34. **Ramage JK**, Williams R, Buxton-Thomas M. Imaging of secondary neuroendocrine tumours of the liver: Comparison of I¹²³ Metaiodobenzylguanidine (MIBG) and In¹¹¹-labelled octreotide (Octreoscan). QJM 1996;89:539-542.
35. Gill GV, Yong A, Power E, **Ramage JK**. Carcinoid-associated ectopic ACTH syndrome with variable response to octreotide. Postgraduate Medical Journal 1999;75: 98-100.
36. Brooklyn TN, Prouse P, Portmann B, **Ramage JK**. Churg-Strauss syndrome and granulomatous cholangiopathy. Eur J Gastroenterol Hepatol 2000;12:809-11
37. Murphy F, Curry WJ, Heaton N, Stangou A, Buxton-Thomas M, **Ramage JK**. Carcinoid and neuroendocrine tumours: are we making any progress? CME journal Gastroenterology, Hepatology and Nutrition. 2001;4:63-69.
38. Amarapurkar AD, Davies A, **Ramage JK**, Stangou AJ, Wight DG, Portmann BC. Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. Eur J Gastroenterol Hepatol 2003 Feb;15(2):139-43.
39. McCarthy M, **Ramage J**, McNair A, Gane E, Portmann B, Pagliuca A, Rela M, Heaton N, Mufti GJ, Williams R. The clinical diversity and role of chemotherapy in lymphoproliferative disorder in liver

transplant recipients. J Hepatol. 1997 Dec;27(6):1015-21

40. Carcinoid and neuroendocrine tumours: Are we making any progress? [A Stangou, M Buxton-Thomas, JK Ramage – CME Journal Gastroenterology. 2001

41. **Ramage JK**, Davies AH; EORTC Quality of Life Group. Measurement of quality of life in carcinoid/neuroendocrine tumours. Endocr Relat Cancer. 2003 Dec;10(4):483-6. Review.

42. Mahmood A, Poller DN, **Ramage JK**. Are renal microgranulomas related to inflammatory tubular destruction? Journal of Clinical Pathology. 2004;57:551-551.

43. Sheen CL, Lamparelli H, Milne A, Green I, **Ramage JK**. Clinical features, diagnosis and outcome of acute portal vein thrombosis QJM. 2000 Aug;93(8):531-4.

44. Sutcliffe R, Maguire D, **Ramage J**, Rela M, Heaton N Management of Neuroendocrine liver metastases. American J Surgery. 2004 ;187: 39-46

45. Banfield A, Green, S, **Ramage JK**. Neuroendocrine tumour management: a team approach. Hospital medicine 2005;66:37-42.

46. Green S, **Ramage JK**. Small bowel carcinoid tumours. Acta endoscopica 2005;35:187-193.

47. Mahmood A, Needham J, Prosser J, Mainwaring J, Trebble T, Mahy G, **Ramage J**. Prevalence of hyperhomocysteinaemia, activated protein C resistance and prothrombin gene mutation in inflammatory bowel disease. Eur J Gastr and Hepatol. 2005;17:739-44.

48. **Ramage JK**, Davies A et al. Guidelines for the management of gut-related neuroendocrine tumours (including carcinoid). Gut 2005; 54: iv1-iv16.

49. D'HAENS¹, D. HOMMES¹, . ENGELS², F. BAERT³, L. VAN DER WAAIJ⁴, P. CONNOR⁵, J. RAMAGE⁶, O. DEWIT⁷, M. PALMEN⁸, D. STEPHENSON⁸, R. JOSEPH⁹ Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study Alimentary Pharmacology and Therapeutics 2006., 24, [1087–1097](#).

50. Jensen RT, Nierdele B, Mitry E, **Ramage JK** et al. ENETS consensus guidelines: Gastrinoma

(Duodenal and Pancreatic). *Neuroendocrinology* 2006; 84 (3): 173-182.

51. ENETS consensus guidelines in Colorectal NET. **Ramage JK** et al. *Neuroendocrinology*. 2007.

52. Translation procedures for standardised quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. Michael Koller (1), Neil K. Aaronson (2), Jane Blazeby (3,4), Andrew Bottomley (5), Linda Dewolf (5), Peter Fayers (6,7), Colin Johnson (8), **John Ramage** (9), Neil Scott (6), Karen West (10). *European Journal of Cancer*. 2007. 43, (12), 1810-1820

53. Enhanced Liver Fibrosis (ELF) test can predict clinical outcomes in patients with chronic liver disease. Julie Parkes, Paul Roderick, Scott Harris, Christopher Day, David Mutimer, Jane Collier, Martin Lombard, Graeme Alexander, **John Ramage**, Geoffrey Dusheiko, Mark Wheatley, Carol Gough, Alastair Burt, and William Rosenberg *GUT* 2010;**59**:1245-1251

54. Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases J. M. Blazeby, P. Fayers, T. Conroy, O. Sezer, **J. Ramage**, M. Rees, on behalf of the European Organization for Research Treatment of Cancer (EORTC) Quality of Life Group. *BJS* 2009. 291-29

55. A Ahmed, G Turner, B King, L Jones, D Culliford, D McCance, J Ardill, B T Johnston, G Poston, M Rees, M Buxton-Thomas, M Caplin and **J K Ramage** Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. *Endocrine-Related Cancer* 2009; 16 (3): 885 -894 .

56. Carcinoid syndrome: Easily Missed? R Srirajaskanthan, D Shanmugabavan, **J K Ramage**. *BMJ* 2010; 341:c3941

57. Kos-Kudła B, O'Toole D, Falconi M, Gross D, Klöppel G, Sundin A, **Ramage J**, Oberg K, Wiedenmann B, Komminoth P, Van Cutsem E, Mallath M, Papotti M, Caplin M; Palma de Mallorca Consensus Conference Participants. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. *Neuroendocrinology*. 2010;91(4):341-50. doi: 10.1159/000287255. Epub 2010 May 19. PubMed PMID: 20484875.

58. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs) **John K Ramage**, A Ahmed, J Ardill et al *Gut* 2012;61:6-32

59. Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. E Friend, G Yadegarfar, C Byrne, C D Johnson, O Sezer, S Pucciarelli, S P Pereira, W-C Chie, A Banfield and **J K Ramage** on behalf of the EORTC Quality of Life Group. *Br J Cancer* 2011;104: 587-592;

60. Basuroy R, Srirajaskanthan R, **Ramage JK**. A multimodal approach to the management of neuroendocrine tumour liver metastases. *Int J Hepatol*. 2012;2012:819193. doi: 10.1155/2012/819193. Epub 2012 Feb 15. PubMed PMID: 22518323; PubMed Central PMCID: PMC3296190.

61. GLP-1 and Glucagon Secretion from a Pancreatic Neuroendocrine Tumor Causing Diabetes and Hyperinsulinemic Hypoglycemia.

Roberts RE, Zhao M, Whitelaw BC, **Ramage J**, Diaz-Cano S, le Roux CW, Quaglia A, Huang GC, Aylwin SJ.

J Clin Endocrinol Metab. 2012 Jul 6.

62. Yadegarfar G, Friend L, Jones L, Plum LM, Ardill J, Taal B, Larsson G, Jeziorski K, Kwekkeboom D, **Ramage JK**. Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours. Br J Cancer. 2013 Jan 15. doi: 10.1038/bjc.2012.560.

63. Basuroy, R. Srirajaskanthan, R. Prachalias, A. Quaglia, A. **Ramage, J. K.**
-Review article: investigation and management of gastric neuroendocrine tumours
Alimentary Pharmacology & Therapeutics .2014 Published online ahead of print.

64. Wu, J. Srirajaskanthan R, **Ramage JK**. Editorial. Rectal Neuroendocrine Tumours. Digestive Endoscopy 2014. Dig Endosc. 2014 Jul;26(4):532-3

65. Edward M. Wolin, Barbara Jarzab, Barbro Eriksson, Thomas Walter, Christos Toumpanakis, Michael Morse, Paola Tomassetti, Matthias Weber, David Fogelman, **John Ramage**, Donald Poon, Jerry Huang, Michelle Hudson, Xin Zhi, Janice L. Pasioka, Abakar Mahamat, Fredrik Swahn, John Newell-Price, Was Mansoor, Kjell Öberg: A multicenter, randomized, blinded, phase 3 study of pasireotide LAR vs octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. Drug Des Devel Ther. 2015; 9: 5075–5086.

66. ENETS TNM Staging Predicts Prognosis in Small Bowel Neuroendocrine Tumours.

Srirajaskanthan R. Ahmed A. Prachalias A. Srinivasan P. Heaton N. Jervis N. Quaglia A. Vivian G.

Ramage JK. Isrn Oncology Print. 2013:420795, 2013. UI: 23533809

67 Marianne Pavel, Dieter Hörsch, Martyn Caplin, **John Ramage**, Thomas Seufferlein, Juan Valle, Phillip Banks, Pablo Lapuerta, Arthur Sands, Brian Zambrowicz, Douglas Fleming, and Bertram Wiedenmann. Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial. Journal Clinical Endocrinology and Metabolism. 2015.2014-2247

68. SYMPTOMS AND QUALITY OF LIFE IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS

Sebastian Kaupp-Roberts, Rajaventhana Srirajaskanthan, **John K. Ramage** EMJ Oncol. 2015;3[1]:34-40

69.. Debbie L Shawcross, Arthur A Dunk, Rajiv Jalan, Gerald Kircheis, Robert J de Knecht, Wim Laleman,

John K Ramage, Heiner Wedemeyer, Ian EJ Morgan. How to Diagnose and Manage Hepatic

Encephalopathy: A Consensus Statement on Roles and Responsibilities Beyond the Liver Specialist. Eur

Journal Gastro Hepatol. 2015. In press.

70. **Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by Ki67 score – authors' reply.** R. Basuroy,R. Srirajaskanthan,A. Prachalias,A. Quaglia, **J. K. Ramage**. Alimentary Pharmacology and Therapeutics. 2015.

71. Delle Fave, G; O'Toole, D; Sundin, A; Taal, B; Ferolla, P; **Ramage, JK**; Ferone, D; Ito, T; Weber, W; Zheng-Pei, Z; ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms
Neuroendocrinology

72. **Ramage, JK**; De Herder, WW; Delle Fave, Gianfranco; Ferolla, P; Ferone, Diego; Ito, T; Ruszniewski, P; Sundin, A; Weber, W; Zheng-Pei, Z; ENETS Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms

73. Basuroy, Ron; Sarker, Debashis; Quaglia, Alberto; Srirajaskanthan, Rajaventhana; **Ramage, John**;
Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?

74. S D Kaupp-Roberts, G Yadegarfar, E Friend, C M O'Donnell, J W Valle, C Byrne, I Bahar, M Finch-Jones, R Gillmore, C D Johnson, S P Pereira, J K Wiggers, M Pinto, B Al-Sarireh, **J K Ramage** and on behalf of the EORTC Quality of Life Group Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder

75. Brédart, Anne; Beaudeau, Ariane; Young, Teresa; Moura De Albuquerque Melo, Hugo; Arraras, Juan Ignacio; Friend, Liz; Schmidt, Heike; Tomaszewski, Krzysztof A; Bergenmar, Mia; Anota, Amélie; Anna Costantini,Frédéric Marchal,Iwona M. Tomaszewska,Vassilios Vassiliou,Wei-Chu Chie, José Hureaux,Thierry Conroy,**John Ramage**,Franck Bonnetain,Dagmara Kulis,Neil K. Aaronson, and ; for the EORTC Quality of Life GroupThe European organization for research and treatment of cancer—satisfaction with cancer care questionnaire: revision and extended application development
Psycho-Oncology 2016 Wiley Online Library

76. Rindi, Guido; **Ramage, J**; De Herder, Ww; Delle Fave, Gf; Ferolla, P; Ferone, D; Ito, T; Ruszniewski, P; Sundin, A; Weber, W; Consensus Guidelines Update for Colorectal Neuroendocrine Neoplasms (NEN).NEUROENDOCRINOLOGY 2016
 77. Basuroy, Ron; Srirajaskanthan, Raj; **Ramage, John K**; Neuroendocrine Tumors. Gastroenterology Clinics of North America 2016 :45 ;3:487-507 Elsevier
 78. Silaschi, Miriam; Barr, James; Chaubey, Sanjay; Nicou, Niki; Srirajaskanthan, Raj; Byrne, Jonathan; **Ramage, John**; MacCarthy, Philip; Wendler, Olaf; Optimized Outcomes Using a Standardized Approach for the Treatment of Patients with Carcinoid Heart Disease
 79. Rindi, Guido; Delle Fave, Gf; O'Toole, D; Sundin, A; Taal, B; Ferolla, P; **Ramage, J**; Ferone, D; Ito, T; Weber, W; ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. NEUROENDOCRINOLOGY 2016
 80. Basuroy, R; Haji, A; **Ramage, JK**; Quaglia, A; Srirajaskanthan, R; Review article: the investigation and management of rectal neuroendocrine tumours Alimentary Pharmacology & Therapeutics 2016;44:4.332-345.
 - 81 Topping M1, Gray D, Friend E, Davies A, **Ramage J**. A Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours.Neuroendocrinology. 2017 Apr 20. doi: 10.1159/000475793. [
 82. Hicks RJ1, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, Hörsch D, Tiensuu Janson E, **Ramage J**; all other Antibes Consensus Conference participants. Neuroendocrinology. 2017 Apr 13. doi: 10.1159/000475526. [Epub ahead of print] ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.
- Author information
- PMID: 28402980 DOI: 10.1159/000475526

83. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJ, Pape UF, Pascher A, **Ramage J**, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M; all other Antibes Consensus Conference participants.. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. *Neuroendocrinology*. 2017 Feb 25. doi: 10.1159/000464292. [Epub ahead of print] PubMed PMID: 28237989.

84. Silaschi M, Barr J, Chaubey S, Nicou N, Srirajaskanthan R, Byrne J, **Ramage J**, MacCarthy P, Wendler O. Optimized Outcomes Using a Standardized Approach for the Treatment of Patients with Carcinoid Heart Disease. *Neuroendocrinology*. 2017;104(3):257-263. doi: 10.1159/000446213. Epub 2016 Apr 21. PubMed PMID: 27097025.

85 Delays and routes to diagnosis of neuroendocrine tumours.
Basuroy R, Bouvier C, Ramage JK, Sissons M, **Srirajaskanthan R**.
BMC Cancer. 2018 Nov 16;18(1):1122. doi: 10.1186/s12885-018-5057-3.
PMID:30445941

86 van Leeuwen et al. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. *Health and Quality of Life Outcomes* (2018) 16:114

87. Ruben Mujica-Mota ^{1,*}, Jo Varley-Campbell ¹, Irina Tikhonova ¹, Chris Cooper ¹, Ed Griffin ¹, Marcela Haasova ¹, Jaime Peters ¹, Stefano Lucherini ¹, Juan Talens-Bou ¹, Linda Long ¹, David Sherriff ², Mark Napier ³, **John Ramage** ⁴, Martin Hoyle Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. *Health Technology Assessment* Volume: 22, Issue: 49, Published in September 2018 <https://doi.org/10.3310/hta22490>

88. Lowell Anthony, MD1; Claire Ervin, MPH2; Pablo Lapuerta, MD3; Matthew H. Kulke, MD4; Pamela Kunz, MD5; Emily Bergsland, MD6; Dieter Horsch, MD7; David C. Metz, MD8; Janice Pasieka, MD9; Nick Pavlakis, MD10; Marianne Pavel, MD11; Martyn Caplin, MD12; Kjell Oberg, MD, PhD13; John Ramage, MD14 Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. *Clinical Therapeutics*/Volume 39, Number 11, 2017

89. **High-intensity interval training and moderate-intensity continuous training in adults with Crohn's disease: a pilot randomised controlled trial**

Garry A. Tew,^a Dean Leighton,^b Roger Carpenter,^c Simon Anderson,^d Louise Langmead,^e John Ramage,^f

James Faulkner,^g Elizabeth Coleman,^h Caroline Fairhurst,^h Michael Seed,^c Lindsay Bottomsⁱ

BMC Gastroenterology. 2019

90. *Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need*

[Ramage J.K.](#)^a · [Valle J.W.](#)^b · [Nieveen van Dijkum E.J.M.](#)^c · [Sundin A.](#)^d · [Pascher A.](#)^{e,f} · [Couvelard A.](#)^g · [Kloppel G.](#)^h · the ENETS 2016 Munich Advisory Board Participants Neuroendocrinology 2018
<https://doi.org/10.1159/000493767>

91. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis

Marco Carbone Stephen J. Sharp Steve Flack Dimitrios Paximadas Kelly Spiess Carolyn Adgey Laura Griffiths Reyna Lim Paul Trembling Kate Williamson Nick J. Wareham Mark Aldersley Andrew Bathgate Andrew K. Burroughs Michael A. Heneghan James M. Neuberger Douglas Thorburn Gideon M. Hirschfield Heather J. Cordell Graeme J. Alexander David E.J. Jones Richard N. Sandford George F. Mells and the members of the UK-PBC Consortium

First published: 29 July 2015 <https://doi.org/10.1002/hep.28017> Cited by: 78

92. A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important

Johannes M. Giesinger Neil K. Aaronson Juan I. Arraras Fabio Efficace Mogens Groenvold Jacobien M. Kieffer Fanny L. Loth Morten Aa. Petersen John Ramage ... See all authors

First published: 30 August 2017 <https://doi.org/10.1002/pon.4548>

93. The European organization for research and treatment of cancer — satisfaction with cancer care questionnaire: revision and extended application development

Anne Brédart Ariane Beaudéau Teresa Young Hugo Moura De Albuquerque Melo Juan Ignacio Arraras Liz Friend Heike Schmidt Krzysztof A. Tomaszewski Mia Bergenmar Amélie Anot Anna Costantini Frédéric Marchal Iwona M. Tomaszewska Vassilios Vassiliou Wei-Chu Chie José Hureau Thierry Conroy John Ramage Franck Bonnetain Dagmara Kulis Neil K. Aaronson ; for the EORTC Quality of Life Group ... See fewer authors

First published: 13 April 2016 <https://doi.org/10.1002/pon.4127>

94. Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7)

A. Brédart PhD A. Anot PhD T. Young BSc K.A. Tomaszewski MD, PhD, DSc J.I. Arraras PhD H. Moura De Albuquerque Melo MS H. Schmidt MD E. Friend MSc in Health and Clinical Research, BSc (Hons) M. Bergenmar Associate Professor A. Costantini PhD V. Vassiliou PhD, MD J. Hureau PhD, MD F. Marchal PhD, MD I.M. Tomaszewska DDS, PhD W.-C. Chie Professor J. Ramage MD, FRCP A. Beaudéau MA T. Conroy MD E. Bleiker PhD D. Kulis MA F. Bonnetain Professor N.K. Aaronson PhD Professor For the EORTC Quality of Life Group ... See fewer authors

First published: 02 November 2017 <https://doi.org/10.1111/ecc.12786>

95. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR
Author links open overlay panelDavid Cella PhD1Jennifer L.Beaumont MS12Stacie Hudgens MA3Florence Marteau MSc4Marion Feuilly PharmD4Aude Houchard MPH4Pablo Lapuerta MD5John Ramage MD, FRCP (UK)6Marianne Pavel MD78Dieter Hörsch MD, PhD9Matthew H. Kulke MD10
<https://doi.org/10.1016/j.clinthera.2018.10.008>
96. Nutritional and vitamin status in patients with neuroendocrine neoplasms Dominique S V M Clement, Margot E T Tesselaar, Monique E van Leerdam, Raj Srirajaskanthan and John K Ramage. WJG 2019. <https://dx.doi.org/10.3748/wjg.v25.i10.1171>
- 97.Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial)
Neuroendocrinology
2019-01-30 | journal-article
DOI: 10.1159/000497330
- 98.Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors
Seminars in Oncology
2018-08 | journal-article
DOI: 10.1053/j.seminoncol.2018.08.004
- 99.Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
Clinical therapeutics
2018-06 | journal-article
PMID: 29724499DOI: 10.1016/j.clinthera.2018.04.006
- 100.Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.
Health and quality of life outcomes
2018-06 | journal-article
PMID: 29866185DOI: 10.1186/s12955-018-0920-0
- 101.Ileocolonic neuroendocrine tumours identified in the English bowel cancer screening programme. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
2018-04 | journal-article
PMID: 29368418DOI: 10.1111/codi.14033
- 102.A cross-cultural convergent parallel mixed methods study of what makes a cancer-related symptom or functional health problem clinically important.
Psycho-oncology
2018-02 | journal-article

PMID: 28857424DOI: 10.1002/pon.4548

103.Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7).

European journal of cancer care

2018-01 | journal-article

PMID: 29094784DOI: 10.1111/ecc.12786

104. Presenting Symptoms and Delay in Diagnosis of Gastrointestinal and Pancreatic Neuroendocrine Tumours

Neuroendocrinology

2018 | journal-article

DOI: 10.1159/000488510Part of ISSN: 0028-3835Part of ISSN: 1423-0194

105.Manuscript: EP-2019-1035R (accepted for publication sept2019 BJC)

Title: Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015

Authors: Tracey Genus, Catherine Bouvier, Kwok Wong, Rajaventhana Srirajaskanthan, Brian Rous, Denis Talbot, Juan Valle, Mohid Khan, Neil Pearce, Mona Elshafie, Nicholas Reed, Eileen Morgan, Andrew Deas, Ceri White, Dyfed Huws, and John Ramage

Recent Grants received:

EORTC Quality of Life Group grant (E22,500) for phase 4 development of QoL module in Carcinoid / neuroendocrine tumours. 2006. Lead applicant

MAPI institute, USA. \$10,000 grant for development of decision support system for management of NET / carcinoid patients. 2006. Lead Applicant.

Pelican Cancer Foundation. £10,000 for development of QoL module for secondary liver tumours. 2005. Co-applicant

EORTC QoL Group grant for development of QoL Bil21. £100k. 2010.

TRANSNET competitive grant “ towards earlier diagnosis of Neuroendocrine Tumours” 2013. £30k.

EORTC grant applied for 2015. Development of QoL module for pancreatic NET. Awarded 2016

NET patient foundation grant for pNET study £40k 2016

IEL grant for QoL study £65k 2016

Grant from HEIF (Higher Education England Innovation Fund)- HHFT with Winchester University £50k for developing My Medical Record to enable patients to enter QoL data online into the hospital server.

Book Chapters

1. Smith AC, Price AB, **Ramage JK**, Williams JG. Clinicians illustrated dictionary of gastroenterology. Science Press. 1989.
2. **Ramage JK**, Wong PY, Williams R. Long term results and survival after liver transplantation. In: A Guide to Liver Transplantation, Eds Williams R and Tan KC. Churchill Livingstone. 1993.
3. Book review of "Oncologic therapies" eds Vokes and Golomb 2003. Annals of Oncology.
4. Quality of Life issues identified by Healthcare workers and patients with metastatic carcinoid/neuroendocrine tumours. **Ramage JK** in: Pancreatic disease. Eds Imrie and Johnson. Springer Verlag 2003. pp18-22

Peer reviews.

Regular reviewer of articles for Annals of Oncology, European Journal of Cancer, Alimentary Pharmacology and Therapeutics, Quality of Life Research, Endocrine-related cancer and GUT.

EXPERIENCE AND TRAINING IN RESEARCH :

1985-86. Training was provided in basic and clinical research within the Intestinal Diseases Research Unit. I attended full year of the epidemiology and biostatistics course which gives unique training in statistics, and design, method and evaluation of research. The research I did at McMaster has been written up as a thesis for the MD degree (University of London).

MD Thesis: Permeability of the small intestine to ^{51}Cr -EDTA: site mechanisms and significance. The phenomenon of increased permeability of the mucosa of the small intestine to probes has brought much interest, both in the possible aetiology of mucosal inflammation of the small bowel and as a diagnostic tool for following the degree of inflammation. I investigated the relationship of permeability of small probes to permeability of larger protein molecules which would cause the inflammatory response. There was a direct correlation, implying the smaller probes could genuinely be used as markers. The mechanisms of permeation of these probes was assessed by in-vitro studies and the site of permeation in the bowel assessed by human intubation studies both in normal and those with inflammatory bowel disease. The thesis therefore contained basic laboratory work and studies on volunteers and on patients.

Research training

Design, Method and evaluation of clinical trials (one day per week for 1 year) . McMaster University Medical School. 1985-86

EU directive and GCP course refresher 2017

Current research :

My research revolves around

a. Neuroendocrine tumours (NET) of the liver

By collecting data from the NET patients at Kings College and within Wessex , we have epidemiological data on 300 patients having various therapies. I have been involved in

various trials of therapies for these tumours.

b. Quality of life scoring systems in cancer

I lead a group involving 5 European countries where we have developed a scoring system for quality of life in NET's. This is in conjunction with the European Organisation for Research and Treatment of Cancer Quality of life group. The scoring module has completed all 4 phases and is used in many international trials

I have developed a QoL scoring system for cholangiocarcinoma, which is involving 5 centres worldwide including Taiwan and India and Japan.

I have completed 3 phases of a module looking specifically at pancreatic NET.

The projects above therefore have a common theme of patient-related factors and epidemiology in liver tumours. I am hoping to develop them into decision support for patients based on their expected QoL after each therapy.

Committee work.

Member of British Society of Gastroenterology (BSG) Information Technology Committee 1999-present.

Clinical lead in Gastroenterology (BSG appt) at the NHS Information Authority 1999.

Secretary of the Liver section of the BSG 2000-2003

Chairman of the BSG website committee. 2003-2007

Vice-Chairman of the Wessex education subcommittee for training of SpR's in gastroenterology. (1999-)

Member of Information Strategy Programme Board at NHH

Treasurer of UKNET- a group meeting to discuss management of Neuroendocrine tumours.

Grants administrator and previous treasurer (and executive board member) of European Organisation for Research and Treatment of Cancer quality of life group.

Co-ordinator and chair of Wessex Carcinoid Group

Director of research and Development, BNHFT, chair of research advisory group.

Royal College of Physicians Lead for HRG's 2006-2018
Member of RCP Payment by Results committee. 2006-2018
Chair of expert working group for Liver HRG's for NHS information centre. 2002-2018.
Chair UKINETS society . 2015-2018
Wessex Regional Advisor in Gastroenterology to Royal College of Physicians 2017-
Executive member, ENETS.

Recent invited lectures :

.
Multiple lectures and chairs of sessions at ENETS meeting 2014-17 and UKINETS meetings 2014-17,

Wessex regional update in Medicine. Sept 2019
Invited lecture, South Lakes Neuroendocrine Meeting Oct 2019
Organiser and Speaker, KHP Network neuroendocrine meeting. October 2019, London
Speaker and chair of session, UKINETS annual meeting Birmingham December 2019

TEACHING:

Elected as examiner for Membership of the Royal College of Physicians of London 2000- 2015
Royal college of Physicians College tutor, North Hampshire Hospital 2002-2005

Research Management:

I was Research and Development Director at Basingstoke (2006-2016) and also chair for the regional Local research network board (CLRN Board 2010-2-13). This involves examining the methods of working of the NIHR projects within the region, and allocation of funds to the various trusts within the region (£9.8 Million this year), depending on performance.

MANAGEMENT TRAINING

I have attended the Kings Fund College full time courses on management for senior registrars and also a course for consultants. I have completed and passed the Open University course Managing Health Services (course B601) leading to a postgraduate certificate in management. (60 credits towards MBA).